Federal Wearable Push Collides with FDA Deregulation and an Unresolved Privacy Gap

A Government Bet on Biowearables

The United States Department of Health and Human Services is preparing what Secretary Robert F. Kennedy Jr. has called “one of the largest advertising campaigns in HHS history,” aimed at persuading every American to wear a health-tracking device within four years. Kennedy framed the initiative as central to the administration’s “Make America Healthy Again” agenda, arguing that wearables allow people to “see what food is doing to their glucose levels and heart rates” and “begin to make good judgments about their diet, about their physical activity, about the way that they live their lives,” according to Reason.

The push comes at a moment when the wearable health sensor market is expanding rapidly. Devices now track heart rate, blood oxygen saturation, sleep architecture, electrocardiograms, skin temperature, and — increasingly — blood glucose levels. Abbott’s Lingo and Libre Rio continuous glucose monitors received FDA clearance for over-the-counter sale in 2024, while Senseonics’ Eversense 365, the first implantable glucose sensor designed to last a full year, has reached commercial availability. Smart rings from Oura, Samsung, and emerging competitors have turned finger-worn devices into a mainstream health monitoring category.

But as the federal government encourages mass adoption, two parallel policy developments are raising pointed questions about what happens to the data these sensors generate — and who, if anyone, is watching the devices themselves.

FDA Loosens the Regulatory Perimeter

On January 6, 2026, the FDA issued revised guidance on its General Wellness Policy for Low Risk Devices, expanding the category of products that can reach consumers without agency premarket review. The updated policy clarifies that devices using non-invasive sensing — including optical sensors that estimate blood pressure, oxygen saturation, blood glucose, and heart rate variability — can qualify as unregulated “general wellness” products, provided their intended use is strictly wellness-focused and they do not claim to diagnose, prevent, or treat a disease.

The shift is notable because it reverses the FDA’s own recent enforcement posture. In mid-2025, the agency issued a warning letter asserting that products intended to measure or estimate blood pressure are regulated medical devices, not wellness products. The January 2026 guidance effectively walks that position back, opening the door for a new generation of wrist-worn and ring-form-factor sensors to reach the market without clinical validation requirements.

The guidance was issued without a public comment period, according to Reason, drawing criticism from privacy and consumer health advocates who argue that loosening oversight precisely when the government is promoting universal adoption creates a regulatory contradiction.

The HIPAA Blind Spot

The privacy gap at the center of the wearable expansion is structural. The Health Insurance Portability and Accountability Act, the primary federal health privacy law, protects medical records generated within a doctor-patient relationship. It does not cover health data collected by consumer wearables.

That distinction matters because modern biosensors collect data that is, by any functional measure, medical in nature. A continuous glucose monitor worn on the arm tracks interstitial fluid glucose concentrations every few minutes. A smart ring records resting heart rate, heart rate variability, respiratory rate, and body temperature around the clock. An FDA-cleared smartwatch can generate a single-lead electrocardiogram. Yet because these measurements originate from consumer devices rather than clinical settings, they fall “almost entirely outside” both FDA medical-device regulations and HIPAA protections, as Reason reported.

The practical consequence is that wearable sensor data flows to cloud servers operated by device manufacturers, where it can be accessed through legal process, shared with third-party analytics partners, or sold to data brokers — all without violating federal law. Research cited by Reason indicates that wearable sensor data “can be used to infer deeply private information like mood, stress levels, and behavioral patterns — well beyond what users knowingly disclose,” and that despite claims of anonymization, such data “often contains unique and persistent fingerprints that make true anonymization difficult, if not impossible.”

A 2019 analysis published in JAMA warned that insurers could use wearable-derived metrics — weight trends, caloric expenditure, blood pressure patterns — to deny coverage or impose higher premiums. No federal legislation has been enacted since that warning to address the scenario.

Conflicts of Interest in the Policy Chain

The credibility of the federal wearable push has been complicated by financial entanglements among its most visible advocates. Casey Means, President Trump’s nominee for U.S. Surgeon General, co-founded Levels, a company that markets continuous glucose monitors to non-diabetics through monthly subscription plans. The company was valued at $300 million in 2022, according to STAT News. During her February 2026 Senate confirmation hearing, Senator Chris Murphy raised concerns that Means had violated FTC rules by failing to disclose financial relationships to products she promoted, as NPR reported.

Public Citizen found that she failed to disclose sponsored products in approximately 56 percent of promotional posts, according to a FactCheck.org analysis of the hearing. Means has stated she will divest from her companies if confirmed, but her medical license has been inactive since January 2024, and she did not complete her surgical residency, raising separate qualification questions documented by STAT News.

The overlap between policy advocacy and commercial interest does not invalidate the potential health benefits of wearable monitoring, but it does introduce a transparency problem into a campaign that asks Americans to trust both the devices and the institutions promoting them.

The Evidence Gap

Proponents of wearable health monitoring point to a growing body of research suggesting that biosensors can motivate increased physical activity and help patients manage chronic conditions. Studies have found that wearable devices help users change health behaviors and accelerate physical activity adoption. However, digital medicine researchers have noted that long-term health outcome improvements from wearable use remain inconsistent in the research literature.

The gap between sensor accuracy and behavior change is a recurring theme. Devices now measure physiologic signals with increasing precision, but translating continuous data streams into sustained lifestyle changes has proven difficult. A glucose spike displayed on a phone screen does not, by itself, change a diet.

Meanwhile, the environmental costs of mass wearable adoption are beginning to draw attention. A study covered by TechCrunch in January 2026 projected that wearable health devices could generate approximately one million tons of electronic waste by 2050, with the researchers noting that plastics are not the primary material concern — the batteries and circuit boards embedded in disposable sensors like glucose monitors pose the greater recycling challenge.

What Comes Next

The federal government is simultaneously acting as promoter, regulator, and — through the FDA’s loosened guidance — deregulator of an industry that generates some of the most intimate data a consumer device can produce. The HHS advertising campaign has not yet launched, and its scale, budget, and specific partnerships remain undisclosed.

What is clear is that the policy framework has not kept pace with the technology. Wearable sensors are approaching clinical-grade capability while remaining classified as wellness devices. The data they produce is functionally medical but legally unprotected. And the officials championing universal adoption have financial ties to the companies that stand to benefit.

None of these tensions are irreconcilable. Congress could extend HIPAA-like protections to consumer health data. The FDA could require clinical validation for devices that output physiologic parameters traditionally used in medical diagnosis. The administration could impose conflict-of-interest firewalls around its wearable campaign. But until any of those steps are taken, the federal wearable push proceeds on a foundation of deregulation and an open question about who ultimately controls the data.